Here's Why Henry Schein (HSIC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HSIC - Henry Schein, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$85.43
DETAILS
HIGH:
$97.00
LOW:
$64.00
MEDIAN:
$86.00
CONSENSUS:
$85.43
UPSIDE:
15.12%
Stock News
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary c.
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein One, the global leader in dental technology, today announced the release of its [url="]2026 Catalyst Index[/url], the fifth edition of its annual
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why Henry Schein (HSIC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript
Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript
Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Henry Schein (HSIC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises
Henry Schein tops Q1 estimates with 14.8% EPS growth and rising margins, as strong segment performance and market share gains drive solid revenue expansion.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
Henry Schein (HSIC) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.15 per share a year ago.
Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength
Henry Schein on Tuesday reaffirmed its annual forecast after beating Wall Street expectations for first-quarter profit as the medical supplies distributor saw strong demand across its dental business.
Henry Schein Reports First Quarter 2026 Financial Results
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. “I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins. Our growth outlook, combined with the progress made on value-creation initiatives.
Henry Schein to Participate in Upcoming Investor Conferences in May
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conferences in May: Bank of America Healthcare Conference at the Encore Hotel in Las Vegas on May 13, at 2:20 p.m. Pacific time (5:20 p.m. Eastern time) Stifel Jaws & Paws Conference at Lotte Hotel, New York City, on May 27, at 3:00 p.m. Eastern time Henry Schein's presentati.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dentrix Ascend Introduces Next Generation Clinical Workflow Built with AWS
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the launch of its Next Generation Clinical Workflow, a voice-driven, AI-enabled advancement embedded within the Dentrix Ascend platform that transforms how dentistry is delivered at the chairside. The Next Generation Clinical Workflow represents the next step in Henry Schein One's ongoing collaboration with Amazon Web Services (AWS) to bring generative AI into everyday clinical workfl.
Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dentrix Ascend Opens Its MCP Layer, Bringing AI Agents and a Custom Build Platform to Dental Practices
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced support for the Model Context Protocol (MCP), an open layer inside Dentrix Ascend that enables ambitious practices, DSOs, and developers to query their data, run AI agents, and build custom workflows, all within the platform they already use. The Platform Dental AI Runs On Henry Schein One supports more than 100,000 global locations, including approximately 90% of the top DSOs. The co.
Price Targets
Henry Schein price target lowered to $85 from $87 at UBS
$85.00
(was $74.35)
Kevin Caliendo
·
UBS
Henry Schein price target lowered to $82 from $88 at Mizuho
$82.00
(was $74.37)
Mizuho Securities
Henry Schein price target lowered to $97 from $104 at Baird
$97.00
(was $74.37)
Robert W. Baird
Henry Schein price target raised to $64 from $61 at Morgan Stanley
$64.00
(was $78.22)
Erin Wright
·
Morgan Stanley
Henry Schein price target raised to $97 from $79 at Barrington
$97.00
(was $81.60)
Barrington
Henry Schein price target raised to $87 from $75 at Leerink
$87.00
(was $83.35)
Leerink Partners
Henry Schein upgraded to Outperform from Neutral at Baird
$100.00
(was $79.57)
Robert W. Baird
Henry Schein price target raised to $81 from $74 at Mizuho
$81.00
(was $79.98)
Steven Valiquette
·
Mizuho Securities
Henry Schein initiated with an Overweight at Barclays
$86.00
(was $72.86)
Barclays
Henry Schein price target raised to $90 from $83 at Evercore ISI
$90.00
(was $71.69)
Evercore ISI
Henry Schein price target raised to $79 from $78 at Barrington
$79.00
(was $71.32)
Barrington
Henry Schein upgraded to Outperform from In Line at Evercore ISI
$83.00
(was $69.04)
Evercore ISI
Henry Schein price target raised to $75 from $69 at Leerink
$75.00
(was $70.81)
Michael Cherny
·
Leerink Partners
Henry Schein price target lowered to $86 from $90 at Barrington
$86.00
(was $66.24)
Michael Petusky
·
Barrington
CFRA Downgrades Henry Schein (HSIC) to Sell ,'see better near-term upside in pharmaceutical distributors'
$67.00
(was $71.10)
Daniel Rich
·
CFRA
Henry Schein price target raised to $74 from $70 at Evercore ISI
$74.00
(was $69.30)
Elizabeth Anderson
·
Evercore ISI
Baird Upgrades Henry Schein (HSIC) to Outperform
$92.00
(was $70.34)
Jeff Johnson
·
Robert W. Baird
Henry Schein Gears Up For Q3 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
$70.00
(was $64.07)
Jonathan Block
·
Stifel Nicolaus
Henry Schein price target lowered to $80 from $90 at Stifel
$80.00
(was $73.17)
Jonathan Block
·
Stifel Nicolaus
Henry Schein downgraded to Neutral from Outperform at Baird
$88.00
(was $78.82)
Jeff Johnson
·
Robert W. Baird